27 min

Verzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers Breastcancer.org Podcast

    • Science

Dr. Stephen Johnston is professor of breast cancer medicine and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.

At the European Society for Medical Oncology Virtual Congress 2020, Dr. Johnston presented results from the monarchE trial. This study compared treating people diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence with either standard hormonal therapy after surgery or two years of Verzenio (chemical name: abemaciclib) in addition to standard hormonal therapy.

Listen to the podcast to hear Dr. Johnston explain:
the characteristics that make early-stage hormone-receptor-positive, HER2-negative breast cancer have a high risk of recurrence
an overview of the study and its early results
side effects caused by Verzenio seen in the study
the future of using Verzenio to treat early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence


Running time: 27:08Thank you for listening to the Breastcancer.org podcast. Please subscribe on iTunes, Stitcher, Spotify, TuneIn, Google Play, or wherever you listen to podcasts. To share your thoughts about this or any episode, leave feedback on the podcast episode landing page on our website.

Dr. Stephen Johnston is professor of breast cancer medicine and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.

At the European Society for Medical Oncology Virtual Congress 2020, Dr. Johnston presented results from the monarchE trial. This study compared treating people diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence with either standard hormonal therapy after surgery or two years of Verzenio (chemical name: abemaciclib) in addition to standard hormonal therapy.

Listen to the podcast to hear Dr. Johnston explain:
the characteristics that make early-stage hormone-receptor-positive, HER2-negative breast cancer have a high risk of recurrence
an overview of the study and its early results
side effects caused by Verzenio seen in the study
the future of using Verzenio to treat early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence


Running time: 27:08Thank you for listening to the Breastcancer.org podcast. Please subscribe on iTunes, Stitcher, Spotify, TuneIn, Google Play, or wherever you listen to podcasts. To share your thoughts about this or any episode, leave feedback on the podcast episode landing page on our website.

27 min

Top Podcasts In Science

Hidden Brain
Alie Ward
Jordan Harbinger
Bret Weinstein & Heather Heying
Neil deGrasse Tyson
Science Friday and WNYC Studios